Drug Type Trispecific T-cell engager (TriTE) |
Synonyms DR 30312, DR30312 |
Target |
Action stimulants, inhibitors, modulators |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CLDN18.2 inhibitors(Claudin 18.2 inhibitors), albumin modulators(Serum albumin modulators) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Pancreatic Cancer | Clinical | China | 01 Jan 2026 | |
| Stomach Cancer | Clinical | China | 01 Jan 2026 |






